The International Prize – Arrigo Recordati

apply

Privacy Policy

PRIVACY POLICY

Updated on: 16 October 2025

CONTENTS

  1.  PREAMBLE
  2.  WHO PROCESSES YOUR PERSONAL DATA
  3.  WHAT TYPES OF PERSONAL DATA WE PROCESS
  4.  FOR WHAT PURPOSES WE PROCESS YOUR PERSONAL DATA
  5.  HOW WE PROCESS YOUR PERSONAL DATA
  6.  HOW LONG WE PROCESS YOUR PERSONAL DATA
  7.  TO WHOM WE COMMUNICATE AND WHERE WE TRANSFER YOUR PERSONAL DATA
  8.  WHAT ARE YOUR RIGHTS AND HOW YOU CAN EXERCISE THEM
  9. CHANGES TO THIS PRIVACY POLICY

1) PREAMBLE

This document describes the ways in which we operate the website https://prize.recordati.com (“Website“) with respect to the processing of the personal data of users of the Website (“Users” or “you”). The Website is managed by Recordati Industria Chimica e Farmaceutica S.p.A..

When you browse our Website, interact with us, or use our services (“Services“), we may collect and process information and personal data about you. For this reason, in accordance with the applicable provisions of data protection laws, we have created this document (“Privacy Policy“) to describe what personal data we collect, the purposes and methods for processing it and the security measures we take to protect it.

This Privacy Policy exclusively concerns this Website and the processing of data performed by Recordati. Any third-party websites referred to by this Website, including through links, are not covered by the information indicated in this Privacy Policy. For additional processing activities, such as those related to the application and participation in the Arrigo Recordati Prize, we invite you to consult the relevant privacy notice as provided from time to time.

2) WHO PROCESSES YOUR PERSONAL DATA

The data controller is Recordati Industria Chimica e Farmaceutica S.p.A. with registered office in Via Matteo Civitali 1, Milan – Italy (“Recordati“, “we“, “us“), a company of the Recordati Group.

The Data Protection Officer of the Recordati Group can be contacted for any privacy issue arising or in connection with the processing of Personal Data at the following email address: groupDPO@recordati.com.

3) WHAT TYPES OF PERSONAL DATA WE PROCESS

  1. Navigation data: The computer systems and software procedures used to operate this Website acquire, during their normal operation, some personal data whose transmission is implicit in the use of internet communication protocols. This information is not collected to be associated with identified data subjects, but by its very nature could, through processing and association with data held by third parties, allow users to be identified. This category of data includes the IP addresses or MAC addresses of the computers used by users who connect to the Website, the URI (Uniform Resource Identifier) addresses of the requested resources, the time of the request, the method used to submit the request to the server, the size of the file obtained in response, the numerical code indicating the status of the response given by the server (successful, error, etc.) and other parameters related to the user’s operating system and IT environment. These data are used to obtain statistical information on the use of the Website and to check its correct functioning. These data could be used to ascertain responsibility in the event of cyber-crimes against the Website, to the extent permitted by applicable legislation.
  2. Data necessary to access to the website, cookies and other similar technologies: Our Website uses cookies and other tracking technologies; for more information regarding the cookies used on the Website, how they are used and how to manage them, please visit our ;
  3. Data provided via e-mail messages or requests: When e-mail messages are voluntarily sent to the contacts or addresses indicated in the Website, this implies the acquisition of certain items of the requesting party’s personal data, including the requesting party’s e-mail address and the content and details of the message or request sent.

4) FOR WHAT PURPOSES WE PROCESS YOUR PERSONAL DATA

We process your personal data for the following purposes and set out the corresponding legal bases below:

#

Purpose of processing

Legal basis

Types of data

1.      

To operate, provide you with access to our Website, improve it, and troubleshoot any issues.

The processing is based on Recordati’s legitimate interest in presenting its activities to the public, ensuring the functioning of the Website, improving its appearance and user experience.

For this purpose we process data under par. 3, letter a. above.

2.    

To get to know the Users through the use of cookies and similar tracking technologies. For more information visit our .

The processing is based on your consent, where necessary, or on Recordati’s legitimate interest consisting of the interest in ensuring that the Website functions properly, is visible and accessible to users.

For this purpose we process data under par. 3, letter b. above.

3.      

To manage and follow up to any User’s request sent to Recordati.

The processing is based on the performance of a contract to which the User is party or in order to take steps at the request of the data subject prior to entering into a contract.

For this purpose we process data under par. 3, letter c. above.

Provision of your personal data for the purpose under no. 1 above is not mandatory. However, unless you provide your personal data, you will not be able to access and browse the Website and/or use the Services.

Provision of your personal data for the purposes under no. 2 above is not mandatory as it may be based on your prior consent or it is performed in pursuit of a legitimate interest of Recordati, appropriately balanced against your interests in the light of the limits imposed on such processing. You will have the right to object to the processing for such purposes, in the manner set out in paragraph 8 below, subject to our overriding interest in continuing the processing and except where the processing is necessary for exercising or defending a right of ours in court. Further information is also available on our .

The processing of personal data for the purpose under no. 3 above is necessary to take steps at your request and provide any necessary follow up.

5) HOW WE PROCESS YOUR PERSONAL DATA

Your personal data will be processed using electronic means.

The security of your personal data is important to us. We adopt – and require our service providers to adopt – appropriate technical and organizational security measures to prevent the loss or destruction of data, illicit or incorrect use and unauthorized access to data, in compliance with applicable legislation. In addition, the IT systems are configured in such a way that personal and identification data are used only when necessary to achieve the specific processing purposes pursued from time to time.

We implement multiple security technologies and procedures to protect your personal data from the risks described above. However, we would like to point out that electronic transmissions or storage of information are not 100% secure. Therefore, despite the security measures we have put in place to protect your personal data, we cannot guarantee that data loss, misuse or alteration will never occur.

We do not use automated individual decision-making that would have legal effects on you or, similarly, significantly affect you.

6) HOW LONG WE PROCESS YOUR PERSONAL DATA

We retain your personal data only for as long as necessary to fulfill the purposes outlined in this Privacy Policy, including legal, regulatory, and business requirements. The retention period may vary depending on the type of data and the applicable legal obligations. Once the retention period expires, we securely delete or anonymize your data unless further retention is required by law. Notably:

  • For the purposes no. 1 of paragraph 4 above, we process your data for the time necessary to provide the Services to you;
  • For the purpose no. 2 of paragraph 4 above, we process your data for the period outlined within our;
  • For the purpose no. 3 of paragraph 4 above, we process your data for the period necessary to manage and follow up your request.

7) TO WHOM WE COMMUNICATE AND WHERE WE TRANSFER YOUR PERSONAL DATA

Your personal data will be processed by our duly authorised and instructed staff, based on their respective needs. Your data will also be processed by our suppliers for technical and organizational services functional to the processing purposes indicated above, such as providers of technical assistance services for the Website and/or hosting services. All the mentioned service providers act as our data processors on the basis of our instructions and in accordance with the provisions of the contracts they have entered into with us.

We may disclose your personal data to public authorities or bodies and to any other legitimate recipient in accordance with the law. In this case, the recipients will act as independent data controllers according to their respective institutional purposes.

If we are involved in a reorganization, acquisition, or sale of our company or parts of it, we will disclose your personal data to the third parties involved in the process, in accordance with applicable law. Any third party that is the recipient of your personal data as part of this procedure may only use it within the limits established by this Privacy Policy and applicable legislation. To receive the updated list of recipients of your personal data, you can contact us, using the contact details indicated above.

If your data is transferred abroad to countries that do not provide the same level of data protection as your country, we will ensure that the transfer is carried out in accordance with applicable law, i.e. by obtaining your consent, when necessary, or by taking any other measures necessary to ensure equivalent protection of the data being transferred, including, but not limited to, through the signing of standard contractual clauses according to the model developed by the European Commission. You can receive a copy of the relevant safeguards by contact us using the contact details set out in section 2 of this Privacy Policy.

At this stage, we do not transfer your personal data outside of the European Economic Area/country in which Recordati is based.

8) WHAT ARE YOUR RIGHTS AND HOW YOU CAN EXERCISE THEM

Recordati informs you that you will always have the right to withdraw your consent at any time, as well as to exercise, at any time, the following rights (subject to certain limitations/restrictions) by contacting the data controller or the DPO at the addresses indicated above:

  1. the “right of access” to your personal data and, in particular, to obtain confirmation of the existence or otherwise of personal data concerning you;
  2. the “right to rectification“, i.e. the right to request the rectification of inaccurate personal data or the completion of incomplete personal data;
  3. the “right to erasure“, i.e. the right to request the erasure, or transformation into anonymous form, of personal data processed;
  4. the “right to restriction of processing“, i.e. the right to obtain from the data controller the restriction of processing in certain cases provided for pursuant to data protection legislation;
  5. the “right to data portability“, i.e. the right to receive (or to transmit directly to another data controller) personal data in a structured, commonly used and machine-readable format;
  6. the “right to object“, i.e. the right to object, in whole or in part:
  • to the processing of personal data carried out by the data controller for its own legitimate interest; and
  • to the processing of personal data carried out by the data controller for marketing or profiling purposes.

The exercise of the above rights is free of charge. However, we may charge a reasonable fee for the administrative costs of complying with a request if it is manifestly unfounded or excessive, or if an individual requests further copies of their data.

All enquiries, requests or concerns regarding this notice or relating to the processing Personal Data including all requests detailed above, should be sent to GroupDPO@recordati.com.

Recordati may ask you to verify your identity before taking further action following your request to exercise the above Rights.

You may also lodge a complaint with the competent supervisory authority (in particular, with the Data Protection Authority of the Member State of your habitual residence, place of work or place of the alleged violation) if you are of the opinion that your personal data are processed in such a way as to result in violations of applicable data protection legislation. You may also contact the relevant supervisory authority if the exercise of your rights is subject to delay, limitation or exclusion by the data controller.

In order to facilitate the exercise of the right to lodge a complaint, please find below the name and contact details of the supervisory authority of Italy:

The name and contact details of the other supervisory authorities of the European Union are available at the following link: Our Members | European Data Protection Board (europa.eu).

If Legislative Decree No. 196/2003 as subsequently amended and supplemented by Legislative Decree no. 101/2018 (“Italian Privacy Code”) applies to the processing of your personal data, in case of User’s death, the aforesaid rights relating to their personal data may be exercised by anyone who has a personal interest, or acts to protect the User as its representative, or for family reasons worthy of protection pursuant to article 2-terdecies of the Italian Privacy Code. Users may expressly prohibit the exercise by its assignees of some of the rights above by written notice to be sent to Recordati as described above, without prejudice to their right to withdraw or modify such expressed intention later on according to the same procedure.

9) CHANGES TO THIS PRIVACY POLICY

We may update and amend all or part of this Privacy Policy at any time. The version published on the Website is the version currently in force. In the event of a change in the text of this Privacy Policy, we will inform you of such changes with a specific banner, link or pop-up on the home page of the Website.

Prof Sandra Strauss, MD PhD FRCP

Sandra Strauss is Professor of Medical and Teenage Young Adult (TYA) Oncology and a Consultant Medical Oncologist. She specialises in the systemic treatment of bone and soft tissue sarcoma and leads the clinical service at University College London Hospital, part of the London Sarcoma Service, one of the largest sarcoma services in Europe.

Her academic post is based within University College London and is focused on translational and clinical research to develop novel therapies for sarcoma patients. She has over 15 years’ experience as a chief and principal investigator for international and national clinical trials. She chairs the executive committee of the EuroEwing consortium (EEC), a pan-European collaboration that has brought together clinicians, scientists and patient advocates to improve outcome for patients with Ewing sarcoma, conducting practice-changing clinical trials with focused translational research. She chairs the UK NCRI Sarcoma Clinical Studies Group Bone Subgroup and is the current sarcoma track chair of European Society of Medical Oncology (ESMO).

She is an executive Committee member of FOSTER (Fight Osteosarcoma through European Research), a scientific committee member of SIOPE, the European Society of paediatric oncology, and ESMO rare cancer and sarcoma annual meeting.

She is an executive member of the Hibiscus Harmonization International Bone Sarcoma Consortium (HIBiSCus), a member of European Organisation for Research and Treatment of Cancer (EORTC) and Innovative Therapies for Children with Cancer (ITCC) consortium.

Dr. Alice L. Yu, M.D., Ph.D

Alice L. Yu, M.D., Ph.D. is an Academician of Academia Sinica in Taiwan. She has been a Distinguished Chair Professor of the Institute of Stem Cell & Translational Cancer Research at Chang Gung Memorial Hospital & Chang Gung University since 2013 and Professor Emeritus of Pediatrics at the University of California in San Diego.

From 2003 to May 2013, Dr. Yu served as a Distinguished Research Fellow and Associate Director at the Genomics Research Center, Academia Sinica, in Taiwan. Prior to this, she was the Chief of Pediatric Hematology Oncology at the University of California in San Diego. She has been a long-time member of the Children’s Oncology Group in the United States, serving on the Steering Committee of Neuroblastoma. She is also a member of various scientific committees and associations.

As a pioneer in cancer immunotherapy, Dr. Yu has taken an anti-GD2 monoclonal antibody (Dinutuximab) from preclinical to phase III clinical trial, culminating in its FDA approval for the treatment of high-risk neuroblastoma in 2015. This marks the first immunotherapeutic agent to target carbohydrate antigen. Treatment with anti-GD2 has since become standard of care for high risk neuroblastoma. For another prevalent tumor-associated glycan, Globo H, her group has demonstrated the adverse impact of its expression on the clinical outcome of patients with hepatoma, cholangiocarcinoma and gallbladder cancer. She has also uncovered the roles of Globo H in cancer as an immune checkpoint molecule and an angiogenic factors, providing rationales for the development of Globo H-targeted immunotherapeutics.

She received the Lifetime Achievement Award from the Advances in Neuroblastoma Research Association in 2025, Pediatric Oncology Award from the American Society of Clinical Oncology (ASCO) in 2020, Excellence in Technology Transfer Award from Federal Laboratory Consortium, USA in 2016, The 55th Academic Award from the Ministry of Education, The 19th Wang Min-Ning Memorial Award for Outstanding Contribution to the Development Medical Science and Technology, National Health and Society, Year 2000 “Key to Life” Award from Leukemia & Lymphoma Society, USA, etc.

Prof. Robert J. Desnick

Dean for Genetics and Genomic Medicine, Professor and Chairman Emeritus of the Department of Genetics and Genomic Sciences, The Icahn School of Medicine at Mount Sinai, New York City, NY, USA.

Robert J. Desnick is Dean for Genetic and Genomic Medicine and Professor and Chairman Emeritus of the Department of Genetics and Genomic Sciences at the Icahn School of Medicine at Mount Sinai.

In 1977, he joined the Mount Sinai faculty as the Arthur J. and Nellie Z. Cohen Professor of Pediatrics and Genetics, and Chief of Medical and Molecular Genetics. From 1993-2011, he was the first Chairman of the Department of Genetics and Genomic Sciences at Mount Sinai. In 2011 he became the Dean for Genetics and Genomic Medicine.

Dr. Desnick’s research interests include lysosomal storage diseases (LSDs) and the inborn errors of heme biosynthesis, the porphyrias, and in particular, their treatment.

His research efforts led to the Federal Drugs Administration (FDA) – and European Medicine Agency (EMA) – approval of enzyme replacement therapy (ERT) for Fabry disease (Fabrazyme) and on-going ERT clinical trials (FDA “Breakthrough” status) for Niemann- Pick B disease, both in partnership with Genzyme. In addition, he was a scientific founder of Amicus Therapeutics (NASDAQ; FOLD), which is developing oral pharmacologic chaperone therapy for Fabry disease (EMA-approved in 2016), Pompe disease, and other disorders. Currently, his laboratory is using gene editing technology to engineer gene therapy in the mouse model of Fabry disease with Sangamo Therapeutics.

Arrigo Recordati

Arrigo Recordati believed research was the most powerful asset for the pharmaceutical industry. He became head of the family business in 1951, at the age of 23, and transformed the family pharmaceutical laboratory employing 325 people into an international company listed since 1984 on the Italian Stock Exchange.

Arrigo Recordati’s remarkable life came to a premature end at the age of 71, in 1999.

Under his direction, in 1953 the company’s headquarters and pharmaceutical plant moved from Correggio, a small town in the Emilia region of Italy, to Milan, the capital of Italian business. During this time Arrigo Recordati provided the company with a stronger competitive advantage by updating its research facilities with advanced pharmacological laboratories.

In the 1950s and 60s, Arrigo Recordati relied on two strong beliefs: scientific research and internationalization. To maximize the results of Recordati research, he established subsidiaries in Brazil and Mexico. Arrigo Recordati also fostered a close relationship with the United States, signing among other things a strategic partnership agreement with Syntex Corporation (acquired by Roche Corporation in 1990) – at that time a company involved in cutting-edge research on the synthesis of steroid hormones.

Arrigo Recordati strongly believed in the power of scientific research to drive the growth of the pharmaceutical industry and provide products beneficial to public health and individual well-being. Efloxate (1955), a coronary vasodilator for the treatment of cardiovascular disease, was the first compound to originate from Recordati’s research laboratories during Arrigo Recordati’s leadership. Other original molecules developed and marketed during his leadership include: dimefline (1958), a respiratory analeptic, flavoxate (1957), a urinary antispasmodic, tibezonium iodide (1971), an oral antiseptic, fenticonazole (1978), an antimycotic and lercanidipine (1984), a calcium channel blocker for the treatment of hypertension. In particular, flavoxate was the first original New Chemical Entity developed by an Italian company to be approved by FDA (Federal Drug Administration) in the United States.

Arrigo Recordati also believed that even small companies – if managed with vigor and imagination – can compete effectively in the pharmaceutical arena. In 1984 Recordati was listed on the Italian Stock Exchange, completing its transformation from a small, family-run operation to a modern, professional, publicly listed company.

After 48 years of intense and challenging leadership, Arrigo Recordati passed away, leaving a solid, international business projected into the future.